FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022805973> ?p ?o ?g. }

• W2022805973 endingPage "55" @default.
• W2022805973 startingPage "47" @default.
• W2022805973 abstract "Background and aim Elevation of plasma cholesterol and/or triglycerides, and the prevalence of small dense low density lipoproteins (LDL) particles remarkably increase the risk in patients with familial combined hyperlipidemia (FCHL). There are, at present, inconsistent data on the effects of different treatments on size and density of LDL particles in FCHL patients. Methods and results A multicenter, randomized, double-blind, double-dummy, parallel group study was designed to evaluate the effect of 3 months' treatment with atorvastatin (10 mg/day) or pravastatin (20 mg/day) on the lipid/lipoprotein profile and LDL size in a total of 86 FCHL patients. Both statins significantly lowered plasma total and LDL cholesterol, with a significantly higher hypocholesterolemic effect observed with atorvastatin (−26.8±11.1% and −35.9±11.1%, respectively) compared to pravastatin (−17.6±11.1% and −24.5±10.2%). The percent decrease in plasma triglycerides was highly variable, but more pronounced with atorvastatin (−19.8±29.2%) than with pravastatin (−5.3±48.6%). Opposite changes in LDL size were seen with the 2 treatments, with increased mean LDL particle diameter with atorvastatin, and decreased diameter with pravastatin, and significant between treatment difference in terms of percent modification vs baseline (+0.5±1.6% with atorvastatin vs −0.3±1.8% with pravastatin). Conclusions The present results support the evidence indicative of a greater hypocholesterolemic effect of atorvastatin compared to pravastatin, and in addition show a raising effect of atorvastatin on the size of LDL particles in FCHL patients. Elevation of plasma cholesterol and/or triglycerides, and the prevalence of small dense low density lipoproteins (LDL) particles remarkably increase the risk in patients with familial combined hyperlipidemia (FCHL). There are, at present, inconsistent data on the effects of different treatments on size and density of LDL particles in FCHL patients. A multicenter, randomized, double-blind, double-dummy, parallel group study was designed to evaluate the effect of 3 months' treatment with atorvastatin (10 mg/day) or pravastatin (20 mg/day) on the lipid/lipoprotein profile and LDL size in a total of 86 FCHL patients. Both statins significantly lowered plasma total and LDL cholesterol, with a significantly higher hypocholesterolemic effect observed with atorvastatin (−26.8±11.1% and −35.9±11.1%, respectively) compared to pravastatin (−17.6±11.1% and −24.5±10.2%). The percent decrease in plasma triglycerides was highly variable, but more pronounced with atorvastatin (−19.8±29.2%) than with pravastatin (−5.3±48.6%). Opposite changes in LDL size were seen with the 2 treatments, with increased mean LDL particle diameter with atorvastatin, and decreased diameter with pravastatin, and significant between treatment difference in terms of percent modification vs baseline (+0.5±1.6% with atorvastatin vs −0.3±1.8% with pravastatin). The present results support the evidence indicative of a greater hypocholesterolemic effect of atorvastatin compared to pravastatin, and in addition show a raising effect of atorvastatin on the size of LDL particles in FCHL patients." @default.
• W2022805973 created "2016-06-24" @default.
• W2022805973 creator A5012854619 @default.
• W2022805973 creator A5012961676 @default.
• W2022805973 creator A5024779399 @default.
• W2022805973 creator A5040984253 @default.
• W2022805973 creator A5056606171 @default.
• W2022805973 creator A5057717851 @default.
• W2022805973 creator A5070705332 @default.
• W2022805973 creator A5087382834 @default.
• W2022805973 creator A5090543140 @default.
• W2022805973 date "2005-02-01" @default.
• W2022805973 modified "2023-10-03" @default.
• W2022805973 title "Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin" @default.
• W2022805973 cites W1975051427 @default.
• W2022805973 cites W1978339749 @default.
• W2022805973 cites W1979888194 @default.
• W2022805973 cites W1982431978 @default.
• W2022805973 cites W1994387199 @default.
• W2022805973 cites W2001609780 @default.
• W2022805973 cites W2007576831 @default.
• W2022805973 cites W2007839248 @default.
• W2022805973 cites W2022555391 @default.
• W2022805973 cites W2023390812 @default.
• W2022805973 cites W2031185570 @default.
• W2022805973 cites W2041752824 @default.
• W2022805973 cites W2043180355 @default.
• W2022805973 cites W2058624028 @default.
• W2022805973 cites W2060480041 @default.
• W2022805973 cites W2073723712 @default.
• W2022805973 cites W2074539024 @default.
• W2022805973 cites W2093987460 @default.
• W2022805973 cites W2094314743 @default.
• W2022805973 cites W2104093244 @default.
• W2022805973 cites W2124712814 @default.
• W2022805973 cites W2135183362 @default.
• W2022805973 cites W2142802148 @default.
• W2022805973 cites W2149677053 @default.
• W2022805973 cites W2152086330 @default.
• W2022805973 cites W2155315233 @default.
• W2022805973 cites W2155481867 @default.
• W2022805973 cites W2157693395 @default.
• W2022805973 cites W2160760242 @default.
• W2022805973 cites W2161721693 @default.
• W2022805973 cites W2169705571 @default.
• W2022805973 cites W2170582496 @default.
• W2022805973 cites W2171880393 @default.
• W2022805973 cites W2216055948 @default.
• W2022805973 cites W4235385580 @default.
• W2022805973 cites W4254869113 @default.
• W2022805973 doi "https://doi.org/10.1016/j.numecd.2004.08.001" @default.
• W2022805973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15871851" @default.
• W2022805973 hasPublicationYear "2005" @default.
• W2022805973 type Work @default.
• W2022805973 sameAs 2022805973 @default.
• W2022805973 citedByCount "33" @default.
• W2022805973 countsByYear W20228059732012 @default.
• W2022805973 countsByYear W20228059732015 @default.
• W2022805973 countsByYear W20228059732016 @default.
• W2022805973 countsByYear W20228059732017 @default.
• W2022805973 countsByYear W20228059732018 @default.
• W2022805973 countsByYear W20228059732019 @default.
• W2022805973 countsByYear W20228059732020 @default.
• W2022805973 countsByYear W20228059732023 @default.
• W2022805973 crossrefType "journal-article" @default.
• W2022805973 hasAuthorship W2022805973A5012854619 @default.
• W2022805973 hasAuthorship W2022805973A5012961676 @default.
• W2022805973 hasAuthorship W2022805973A5024779399 @default.
• W2022805973 hasAuthorship W2022805973A5040984253 @default.
• W2022805973 hasAuthorship W2022805973A5056606171 @default.
• W2022805973 hasAuthorship W2022805973A5057717851 @default.
• W2022805973 hasAuthorship W2022805973A5070705332 @default.
• W2022805973 hasAuthorship W2022805973A5087382834 @default.
• W2022805973 hasAuthorship W2022805973A5090543140 @default.
• W2022805973 hasConcept C126322002 @default.
• W2022805973 hasConcept C134018914 @default.
• W2022805973 hasConcept C185592680 @default.
• W2022805973 hasConcept C2777482532 @default.
• W2022805973 hasConcept C2778163477 @default.
• W2022805973 hasConcept C2779091943 @default.
• W2022805973 hasConcept C2779519902 @default.
• W2022805973 hasConcept C3019550498 @default.
• W2022805973 hasConcept C555293320 @default.
• W2022805973 hasConcept C62746215 @default.
• W2022805973 hasConcept C71924100 @default.
• W2022805973 hasConceptScore W2022805973C126322002 @default.
• W2022805973 hasConceptScore W2022805973C134018914 @default.
• W2022805973 hasConceptScore W2022805973C185592680 @default.
• W2022805973 hasConceptScore W2022805973C2777482532 @default.
• W2022805973 hasConceptScore W2022805973C2778163477 @default.
• W2022805973 hasConceptScore W2022805973C2779091943 @default.
• W2022805973 hasConceptScore W2022805973C2779519902 @default.
• W2022805973 hasConceptScore W2022805973C3019550498 @default.
• W2022805973 hasConceptScore W2022805973C555293320 @default.
• W2022805973 hasConceptScore W2022805973C62746215 @default.
• W2022805973 hasConceptScore W2022805973C71924100 @default.
• W2022805973 hasIssue "1" @default.
• W2022805973 hasLocation W20228059731 @default.

• next